Definitive Healthcare (NASDAQ:DH) Releases FY 2024 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 0.320-0.340 for the period, compared to the consensus estimate of 0.370. The company issued revenue guidance of $247.0 million-$251.0 million, compared to the consensus revenue estimate of $258.3 million. Definitive Healthcare also updated its FY24 guidance to $0.32-0.34 EPS.

Definitive Healthcare Trading Down 6.3 %

DH stock traded down $0.25 during midday trading on Friday, reaching $3.70. 1,732,976 shares of the company’s stock traded hands, compared to its average volume of 802,780. The company has a market capitalization of $436.34 million, a P/E ratio of -2.26, a PEG ratio of 3.08 and a beta of 1.30. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.30 and a quick ratio of 2.30. Definitive Healthcare has a fifty-two week low of $3.19 and a fifty-two week high of $11.60. The business has a 50-day moving average price of $5.48 and a two-hundred day moving average price of $7.09.

Definitive Healthcare (NASDAQ:DH) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.04). The firm had revenue of $63.48 million for the quarter, compared to analysts’ expectations of $64.00 million. Definitive Healthcare had a negative net margin of 78.16% and a positive return on equity of 0.51%. Equities research analysts forecast that Definitive Healthcare will post 0.09 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. William Blair reaffirmed an outperform rating on shares of Definitive Healthcare in a research note on Tuesday, May 14th. Deutsche Bank Aktiengesellschaft cut their target price on Definitive Healthcare from $10.00 to $7.00 and set a hold rating on the stock in a research note on Thursday, May 9th. Canaccord Genuity Group cut their target price on Definitive Healthcare from $10.00 to $8.00 and set a hold rating on the stock in a research note on Wednesday, May 8th. Robert W. Baird cut their target price on Definitive Healthcare from $8.00 to $6.00 and set a neutral rating on the stock in a research note on Wednesday. Finally, JPMorgan Chase & Co. downgraded Definitive Healthcare from a neutral rating to an underweight rating and cut their target price for the company from $7.00 to $5.00 in a research note on Wednesday. One analyst has rated the stock with a sell rating, nine have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of Hold and a consensus target price of $8.45.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.